

Investigator Gazetteer Report – Oncology Trials - Feb 2021

Oncology Trials

By Johan PE Karlberg, MD, PhD

<https://www.clinicaltrialmagnifier.org/>

Objective and Material

The objective of this report is to display the number and type of industry-sponsored oncology clinical trials.

The data represent industry-sponsored phase II/III clinical trials for a four year period, i.e. for trials registered with the US trial registry (clinicaltrials.gov) between January 1, 2017 to December 31, 2020.

Results

The results are shown in Table 1 and Table 2.

Oncology Trials – Globally

Table 1. Oncology trials globally: Number of industry-sponsored phase II/III oncology - trials and subjects - by cancer type over a period of four full consecutive years (2017.01-2020.12).

The top 10 cancer types represent together 67.9% and 69.1% of all trials and subjects respectively.

CANCER TYPE	RANK	TRIALS (N)	TRIALS (%)	SUBJECTS (N)	SUBJECTS (%)
ONC RESP: LUNG	1	295	17.1	83,871	18.3
ONC BREAST	2	189	11.0	63,443	13.9
ONC HEM: LYMPHOMA	3	137	7.9	19,909	4.4
ONC SOLID TUMOR/CANCER	4	114	6.6	23,852	5.2
ONC HEM: LEUKEMIA	5	96	5.6	17,373	3.8
ONC GI: ESOPHAGEAL/GASTRIC	6	71	4.1	26,839	5.9
ONC OG: OVARY	7	70	4.1	18,331	4.0
ONC UROLOGY: PROSTATE	8	70	4.1	26,479	5.8
ONC ENT: NPC	9	68	3.9	13,323	2.9
ONC UROLOGY: BLADDER	10	61	3.5	22,819	5.0
ONC GI: LIVER	11	60	3.5	20,679	4.5
ONC GI: COLORECTAL	12	57	3.3	13,375	2.9
ONC HEM: MYELOMA	13	54	3.1	10,833	2.4
ONC DERM: MELANOMA	14	53	3.1	15,119	3.3
ONC CNS: GLIOMA	15	38	2.2	3,844	0.8
ONC GI: PANCREAS	16	38	2.2	8,473	1.9
ONC OG: CERVIX	17	35	2.0	19,933	4.4
ONC UROLOGY: KIDNEY	18	32	1.9	11,251	2.5
ONC GI: BILIARY	19	27	1.6	6,652	1.5
ONC OG: UTERUS	20	25	1.5	9,323	2.0
ONC HEM: MYELODYSPLASTIC	21	20	1.2	3,558	0.8
ONC CHEMOTHER EFFECTS	22	14	0.8	2,004	0.4
ONC ORTH: SARCOMA	23	13	0.8	1,336	0.3
ONC DERM: SKIN	24	11	0.6	1,845	0.4
ONC ENDO: NEUROENDO	25	10	0.6	577	0.1
ONC GI: GASTROINTESTINAL	26	10	0.6	2,485	0.5
ONC CNS: BRAIN	27	7	0.4	797	0.2
ONC ORTH: BONE	28	7	0.4	3,315	0.7
ONC RESP: PLEURA	29	7	0.4	1,209	0.3
ONC CANCER PAIN/CACHEXIA	30	6	0.4	1,019	0.2
ONC ENDO: THYROID	31	6	0.4	1,120	0.2
ONC HEM: CANCER	32	6	0.4	921	0.2
ONC CNS: NEUROBLASTOMA	33	5	0.3	359	0.1
ONC METASTATIC	34	3	0.2	668	0.2
ONC DERM: BASAL CELL	35	2	0.1	365	0.1
ONC GI: THYMUS	36	2	0.1	100	0.0
ONC DERM: KAPOSI	37	1	0.1	45	0.0
ONC ENDO: PARATHYROIDEA	38	1	0.1	10	0.0
ONC ENDO: PITUITARY	39	1	0.1	150	0.0
ONC GI: GERM	40	1	0.1	19	0.0
ONC ORTH: LIPOMA	41	1	0.1	38	0.0
ONC UROLOGY: PENIS	42	1	0.1	18	0.0

Investigator Gazetteer Report – Oncology Trials - Feb 2021

The top five cancer type in the US are the same as those identified globally (Tables 1-2).

The top 10 cancer types in the US represent together 67.7% and 72.6% of all trials and sites respectively.

About one in four trials is conducted in lung cancer or breasts cancer both globally and in the US.

Table 2. Oncology trials in the US: Number of industry-sponsored phase II/III oncology - trials and sites - by cancer type over a period of four full consecutive years (2017.01-2020.12).

CANCER TYPE	RANK	TRIALS (N)	TRIALS (%)	SITES (N)	SITES (%)
ONC RESP: LUNG	1	131	14.5	2,661	13.8
ONC BREAST	2	93	10.3	2,957	15.4
ONC SOLID TUMOR/CANCER	3	73	8.1	1,194	6.2
ONC HEM: LYMPHOMA	4	64	7.1	1,114	5.8
ONC HEM: LEUKEMIA	5	53	5.9	868	4.5
ONC UROLOGY: PROSTATE	6	47	5.2	1,922	10.0
ONC UROLOGY: BLADDER	7	45	5.0	913	4.7
ONC HEM: MYELOMA	8	39	4.3	494	2.6
ONC OG: OVARY	9	34	3.8	1,361	7.1
ONC DERM: MELANOMA	10	33	3.7	500	2.6
ONC ENT: NPC	11	30	3.3	418	2.2
ONC GI: COLORECTAL	12	29	3.2	406	2.1
ONC GI: ESOPHAGEAL/GASTRIC	13	28	3.1	453	2.4
ONC GI: PANCREAS	14	24	2.7	462	2.4
ONC UROLOGY: KIDNEY	15	23	2.5	457	2.4
ONC GI: LIVER	16	21	2.3	404	2.1
ONC CNS: GLIOMA	17	19	2.1	363	1.9
ONC OG: UTERUS	18	18	2.0	646	3.4
ONC GI: BILIARY	19	13	1.4	219	1.1
ONC HEM: MYELOYDYSPLASTIC	20	13	1.4	391	2.0
ONC DERM: SKIN	21	11	1.2	131	0.7
ONC OG: CERVIX	22	11	1.2	180	0.9
ONC CHEMOTHER EFFECTS	23	8	0.9	93	0.5
ONC ORTH: SARCOMA	24	7	0.8	96	0.5
ONC CNS: BRAIN	25	5	0.6	113	0.6
ONC ENDO: NEUROENDO	26	5	0.6	9	0.1
ONC HEM: CANCER	27	5	0.6	59	0.3
ONC RESP: PLEURA	28	4	0.4	34	0.2
ONC CANCER PAIN/CACHEXIA	29	3	0.3	54	0.3
ONC CNS: NEUROBLASTOMA	30	3	0.3	23	0.1
ONC GI: GASTROINTESTINAL	31	3	0.3	65	0.3
ONC DERM: BASAL CELL	32	2	0.2	30	0.2
ONC ENDO: THYROID	33	2	0.2	54	0.3
ONC METASTATIC	34	2	0.2	102	0.5
ONC DERM: KAPOSII	35	1	0.1	16	0.1
ONC GI: GERM	36	1	0.1	3	0.0
ONC ORTH: BONE	37	1	0.1	5	0.0